Versant Ventures launched build-to-buy Quanticel Pharmaceuticals Inc. in partnership with Celgene Corp. in 2011. Three-and-a-half years later, in April 2015, Celgene bought the company and its single-cell tumor genome analysis platform outright. [See Deal]
The partners apparently enjoyed the experience so much that they’re doing it again. On December 10, Inception Sciences announced the...
Welcome to Scrip
Create an account to read this article
Already a subscriber?